Isis To Receive $26.5 Million From Alnylam

Isis Pharmaceuticals Inc. (ISIS) will receive $26.5 million in upfront fees from Alnylam as part of its share of the agreement between Alnylam and Roche. The stock price climbed $1.73 to close at $11.80.